Exact Sciences, a prominent provider of cancer screening and diagnostic tests, has announced the appointment of Aaron Bloomer as Chief Financial Officer, effective May 15, 2024. With over 15 years of finance and accounting experience, Bloomer brings a wealth of expertise to his new role.
Bloomer's distinguished career includes leadership positions at renowned companies such as Baxter International and 3M, where he played instrumental roles in improving financial performance, driving operational excellence, and spearheading strategic growth initiatives. At Baxter, he led corporate financial planning, reporting, and analytics as vice president, while at 3M, he served as senior vice president of FP&A and held the position of CFO for 3M China and one of the company's divisions in Tokyo, Japan.
Kevin Conroy, Chairman and CEO of Exact Sciences, expressing his enthusiasm for Bloomer's appointment said, "Aaron comes to us with significant global experience setting corporate strategy and driving growth and operational discipline from his leadership roles at incredible companies," Conroy emphasized, “As we look to bring our portfolio of tests to more patients around the world, Aaron’s oversight will help us further our mission of helping to eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment."
To ensure a seamless transition, Bloomer joined Exact Sciences immediately as Executive Vice President, Finance, and will officially assume the CFO role after a 30-day transition period, succeeding Jeff Elliott. Elliott will then transition to the role of Special Advisor to the CEO, as previously announced.
In response to his appointment, Bloomer expressed his excitement to contribute to Exact Sciences' mission-driven growth trajectory. He pledged to leverage his competitive and innovative mindset to drive superior financial and operational execution as CFO.
Exact Sciences is renowned for providing patients and healthcare professionals with the clarity needed to take life-changing action earlier in the fight against cancer. Building upon the success of its Cologuard and Oncotype tests, the company is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.
Bloomer's appointment underscores Exact Sciences' commitment to enhancing its leadership team with top-tier talent to further advance its mission and strategic objectives. With Bloomer at the financial helm, Exact Sciences is poised to continue its trajectory of innovation and impact in the field of cancer diagnostics and treatment.
